Through its diversity initiatives and social media campaign—complete with the hashtag #BlackFamCan—the FDA hopes to improve health equity for patients with cancer and their families.
Building up to National Black Family Cancer Awareness Week (June 13-19), the US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) hosted a community forum on Tuesday, May 21. Lailea Noel, PhD, MSW, who is an Association of Cancer Care Centers (ACCC) Board of Trustees member; assistant professor, Meadows Foundation Fellow in Quality of Life in the Rural Environment; director, Institute for Collaborative Health Research and Practice, Steve Hicks School of Social Work; and affiliate assistant professor of Oncology and Health Social Work, Dell Medical School, The University of Texas at Austin, joined thought leaders across the oncology world for a discussion about engaging multiple generations in cancer discourse. Through its diversity initiatives, science and technology, community engagement, and social media campaign—complete with the hashtag #BlackFamCan—the FDA hopes to improve health equity for patients with cancer and their families.
Rea Blakey, associate director, External Outreach and Engagement, OCE, FDA, provided opening remarks before introducing the first speaker of the day: Melissa A. Edwards, PhD, deputy executive director, President’s Council of Advisors on Science and Technology, Executive Office of the President, White House.
For Dr. Edwards, the devastating effects cancer can have on a patient were clear to her early in life following her aunt’s diagnosis with the disease. “I did my best to help my aunt navigate her diagnosis as she was exposed to treatments and chemotherapy for the first time,” Dr. Edwards said. “[But] I felt helpless in this new, confusing environment because I didn’t have a good sense of the resources available to my family.” According to Dr. Edwards, when her aunt died, it left a painful, lasting impact, along with a fear of talking about cancer at all.
While attending medical school years later, Dr. Edwards began studying cancer immunology. “This allowed me to combat my fear with knowledge,” she said. Dr. Edwards acknowledged that for children and young adults, it is easy to shrink back and feel intimidated by a cancer diagnosis. However, she emphasized the importance of the friends and family members of a recently diagnosed patient with cancer, asking questions, engaging in research, and exploring every resource available to them.
Following Dr. Edwards’s address, Asma Dilawari, MD, medical oncologist, Division of Oncology 1, Office of Oncologic Diseases, FDA, discussed the issues the FDA hopes to solve with its diversity initiatives. “One of the most rewarding parts since joining the FDA is [developing] all these initiatives that address the problems in private practice,” she said. “When you see a problem that has come up for many years, you want to start the change.”
According to Dr. Dilawari, one of these issues has been a lack of diversity in the clinical trial pool. “We study drugs and products often on a homogenous population and everyone has access to it, but we don’t have enough data,” she explained. “A lot of diversity plans have touted working with patients, advocates, and community organizations… to start a conversation from all angles on working together to tackle this problem of underrepresentation in clinical trial research.”
According to Dr. Dilawari, the FDA developed diversity plans and guidelines to provide specific measures to companies—who are developing and marketing drugs in the United States—focused on ensuring diverse representation in their clinical trial testing population. The initiatives are designed to spark important conversations among drug developers, patient navigators, and others about diversifying cancer drug research and clinical trials. Blakely echoed Dr. Dilawari’s sentiments about the benefits of the FDA’s guidelines while highlighting the need for a collaborative approach to improving clinical trial diversity. “There are limitations on what we, the FDA, can do. So, we need all of you,” Blakey said.
The forum shifted toward the patient experience once more with Byron Daily, national senior manager of Community Outreach-Myeloma Link, The Leukemia and Lymphoma Society, who discussed the value of patient advocacy. A survivor of cancer, Daily shared his experience as a patient navigating the cancer care continuum.
“My story began in 2018 when I was diagnosed with multiple myeloma. We did not have a history of cancer in my family, so it came as a surprise,” he said. “I kept myself in good shape, and I thought I was eating the right things, so I was surprised.” Daily believes he was lucky to have a good primary care physician before and following his diagnosis and praised the impact his provider had on his cancer journey.
“My doctor noticed small red flags, and that ultimately led to my diagnosis,” he said. “I was also fortunate to have access to a number of life-saving resources, including good health insurance.” While Daily had the good fortune of being surrounded by people and systems that guided him through successful treatment, many Black patients with cancer and their families do not.
Approximately 8 months following his diagnosis, Daily underwent a bone marrow transplant and spent the next 90 days in recovery. According to Daily, those days were filled with thoughts on ways to give back to his community and advocate for financial literacy among Black families. Now, at The Leukemia and Lymphoma Society, Daily partners with community fixtures like churches and food banks to spread the word about free resources that are available to patients with cancer and their families.
“I appreciate you telling your personal story because a lot of people don’t realize that because they feel good doesn’t mean there isn’t a need for them to see a health care provider,” Blakey said to Daily following his remarks. Then she introduced Dr. Noel to discuss her work, and ACCC’s commitment to reimagining community engagement.
“Thank you for the opportunity to be a part of this event,” Dr. Noel said. “ACCC’s work focuses on those cancer care programs and practices that reach out to different communities across the country, so I think we can be a valuable partner to the FDA.” Dr. Noel discussed ACCC’s mission to bring together cancer programs and practices nationwide to advance health equity for patients with cancer, with a focus on reaching out to smaller rural communities with minimal access to resources.
Dr. Noel went on to discuss how and why ACCC president Nadine J. Barrett, PhD, MA, MS, senior associate dean for Community Engagement and Equity in Research at the Wake Forest University School of Medicine and Atrium Health, centered her President’s Theme on reimagining community engagement and equity in cancer. “In conjunction with this theme—and Juneteenth—ACCC will host a webinar on Tuesday, June 18 during #BlackFamCan week,” Dr. Noel said. “Dr. Barrett will join AACI's [Association of American Cancer Institutes] president Dr. Robert Winn [director, and Lipman chair in Oncology, VCU Massey Comprehensive Cancer Center] to discuss their shared organizational goal of advancing equitable cancer care.”
Dr. Noel concluded by sharing her own powerful experience with community work in rural patient populations. Troubled by learning that Black women dying of breast cancer before the age of 40 is a common occurrence, Dr. Noel was moved to bring educational resources and treatment options to patients who are unable to travel to major cities to receive treatment. “That experience helped me understand how vital the work done in these communities is,” she concluded.
“As I am sitting here, I am almost in tears. Dr. Noel, Dr. Barrett is my hero… It is scary, it is hard. For most of my community, the closest thing we see to a primary care physician is the emergency room,” said B. Angeloe Burch Sr., PhD, executive director, African American Dance Ensemble, CEO, African American Community Collaborative, Inc., president, Durham, NC Branch NAACP, parliamentarian, State NAACP, chair, Families and Communities Rising, Inc. “They don’t have someone they can talk to; they don’t know these people and these people don’t know them. And when cancer comes, it comes hard, so they have to decide if they want treatment or if they want to die.”
As the day’s final speaker, Dr. Burch discussed how culture and the arts—specifically African American dance—can be a powerful unifier in Black communities and offset the hesitation of having conversations about health care, diagnosis, and treatment. Dr. Burch also believes that health care teams should endeavor to recruit providers that care about the members of the community they hope to address.
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
